The Pear Team

Leadership Team

Corey McCann

Founder and Chief Executive Officer

Boston, MA • San Francisco, CA

Corey is a physician, scientist, entrepreneur, and healthcare investor.

Previously, he was an investor with MPM Capital and with RiverVest Venture Partners, where he evaluated new investment opportunities, managed relationships with strategic partners, and oversaw board-level strategy and execution at portfolio companies. Prior to MPM, he was with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey’s Central Nervous System (CNS) expertise group, serving clients across pharma and biotech.  He is a founding member of multiple start-ups including Alcyone Lifesciences, a company developing technologies to deliver therapeutics to the brain.

Dr. McCann’s post-graduate training was at Harvard University, Washington University in St Louis, and at the Massachusetts General Hospital, and he graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar.

previous next

Corey

Ian McFarland

General Manager, Chief Technology Officer

San Francisco, CA

Ian is an entrepreneur and technologist. He’s the Founder and Chairman of Neo, a leading global product innovation company.

He has a long track record of identifying trends early: he started working on worldwide distributed Hypertext systems in 1989 with Ted Nelson at Autodesk, about the same time Tim Berners-Lee started working on the World Wide Web. At Wired Magazine in 1994 he was on the launch team of HotWired, the first significant commercial Web application. There he worked with Brian Behlendorf on patches to NCSA HTTP, what would eventually become Apache, the basis of the Apache Software Foundation. In 1995 Ian met James Gosling at a demo of the new programming language Java, and subsequently built the first client server application ever written in Java, a technology demo for Sun’s announcement of the language at SunWorld.

In 2004 Ian joined Friendster as employee number 3 and Chief Architect, the company that created the phenomenon we know today as Social Networking. In 2005 he joined Pivotal Labs, and as VP of Technology helped to build one of the most trusted brands in agile development consulting, and the first major consultancy to embrace Ruby on Rails. In 2009 he was part of the summit of design and technology leaders like Alan Cooper and Ward Cunningham that developed the integration of agile principals into design that would come to be known as Lean UX.

In 2011, Ian left Pivotal Labs to join Digital Garage, a publicly traded Japanese company founded by Joi Ito, Director of the Media Lab at MIT, as Group CTO, and with the help of Eric Ries, author of the Lean Startup movement, to start building the consultancy he launched in 2012, Neo Innovation, Inc., of which he is Founder and Chairman.

Ian has advised the White House Office of Science and Technology Policy and 18F, and has been a mentor and speaker at various accelerator programs, including 500 Startups, Tech Stars; Haxlr8r and Highway1 (Hardware accelerators, in Shenzhen, China, and San Francisco, respectively); and IndieBio (Sythetic Biology accelerator in San Francisco).  He is an author and frequent speaker on Entrepreneurship, Lean, Agile, UX and Cloud.

previous next

Ian

Alex Waldron

Chief Commercial Officer

Boston, MA

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.

He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals.

Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

previous next

Alex

Stephen Kennedy Smith, JD

EVP, Corporate Development

Cambridge, MA

Stephen is an entrepreneur, business advisor, and has a long career in the development, funding and expansion of companies. He has served as a director or advisor to several companies, including Gridline Communications Holdings, RAPID Pharmaceuticals, Mainland Resources and, Med-Design Corp.

Stephen is also an active member of the Kennedy family financial advisory board. He served as Deputy Campaign Manager for Senator Edward Kennedy during his presidential and senatorial campaigns, and also served on the staff of the Senate Judiciary and Foreign Relations Committees.

Stephen taught negotiation at Harvard University Law School and is a three-time winner of Harvard’s Danforth Award for Excellence in Teaching and a recipient of the Lyndehurst Foundation prize for social and artistic achievement.

Mr. Kennedy-Smith holds an M.A. from Harvard University, a J.D. from Columbia University, and an M.A. Ed. from Harvard’s School for Education.

previous next

Stephen

David Amor

VP, Regulatory Affairs

San Francisco, CA

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health.

From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements.

Serving as the management representative for multiple medical device and pharmaceutical companies, David has also led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies.

He co-founded RemindTrac in 2014 (www.remindtrac.com), a medication adherence company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

Amor is a Top 40 Under 40 (MDDI 2015) and Top 35 Under 35 (MN Biz 2016) life science consultant and a Fellow Emeritus of the University of Minnesota Medical Device Center.  As an adjunct professor at St. Cloud State University, David teaches graduate level quality, design controls and risk management courses for medical device students and participates in several AAMI Working Groups, including CP (Combination Products) Committee and ISO TC 210.

Lastly, David serves on the board of AdrenaCard, a combination drug-delivery auto-injector and is an active Angel investor for Gopher Angels in the Twin Cities.

previous next

David

Chris Lento, MBA

VP, Commercial Operations

Boston, MA

Christopher S. Lento is an experienced life sciences executive in the biotechnology & pharmaceutical fields.

He has over 25 years of experience in senior leadership roles managing the commercial operations and new product launches at both start-up and established healthcare-focused companies including: Astra-Zeneca, Genentech BioOncology, US Oncology/McKesson, Abraxis Bioscience, ScribesSTAT, Altos Solutions and Galena Biopharma. Chris will be responsible for the US commercialization of Pear’s eFormualations.

Chris received his BSBA, Finance from Providence College and his MBA, Marketing from Montclair State University.

previous next

Chris

Yuri Maricich, MD, MBA

VP, Clinical Development

Boston, MA

Dr. Maricich is a licensed, board-certified physician, investor, and strategist. He works to improve our healthcare system by investing in, advising for, and leading innovative firms.

He has worked with & led successful healthcare & life science (HLS) firms including Xdynia (acquired by Cavion), Corixa (acquired by GlaxoSmithKline) and maintains active patient care practice. He founded a digital health firm as a 3rd year medical student that focused on data-structuring of clinical documents using NLP.  He has worked with & advised a diversity of HLS technology and investment firms, including those focused on cloud computing, digital health, biotech, healthcare, device, and IP law.

Dr. Maricich invests in public and private firms and raised funds.  Current focus includes Big Data, analytics, therapeutics, diagnostics, genomics, delivery, digital health, value-driven care, services & mobile health. He was in Michael Porter’s first Value-Driven Health Care course at Harvard.  As a 2nd year medical student he founded the Pathos Project. He is a published author and frequent speaker.

Dr. Maricich earned his M.D. degree at the University of Washington School of Medicine, his M.B.A. from Harvard Business School, and his undergraduate at the University of Notre Dame, with studies in pre-professional science and philosophy. He completed internal medicine training at the University of Virginia Health System.

previous next

Yuri

Davina Pallone

VP, Product Development

San Francisco, CA

Davina thrives on solving problems and finding creative, elegant ways to present complex information. With a background in engineering, technical communication, and fine art, she’s driven to discover the place where value, usability, and feasibility intersect. She excels in clarifying business requirements, stoking the fires of cross-functional teams, and leveraging lean methodologies to roll out successful products on time, regardless of constraints.

In 1998 Davina founded designwrench information arts, a small agency that provided print, identity, and web design and development to businesses and non-profits for over 15 years. In 2014, she joined forces with integrated design and development consultancy Cloud City as their Director of User Experience. While there, she played a key role in building content management systems and marketing websites for the Public Library of Science (PLOS), boosting the power and impact of Open Access scientific publishing.

When she’s not geeking out on process, Davina creates paintings, tapestries, sculptures, and installations inspired by her love of physics, nature, community, and connection.

previous next

Davina

Matthew Smith, PhD

VP, Operations & Strategy

Boston, MA

Matthew is a scientist, strategic consultant, and thought leader.

Prior to joining Pear he held roles actively conducting research on debilitating disorders of the brain, advising life science companies on the scientific and economic potential of novel technologies, and advocating for public awareness and governmental support of biomedical research. He has a passion for building companies around compelling technology, and maintains close ties to, and advisory roles for, numerous start-up life science ventures in both Boston and San Francisco.

As a scientist, Dr. Smith has a particular interest in neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease and has published widely on potential therapeutics mechanisms for combating disease progression.

Matthew received his PhD in Neuropathology from the University of Michigan and completed a post-doctoral fellowship at Harvard University prior to joining the Pear team. Dr. Smith is a member of the American Association for the Advancement of Science, the American Chemical Society, the Alzheimer’s Association, and the Parkinson’s Action Network.

previous next

Matt

Walter Greenleaf, PhD

Chief Science Advisor

Stanford, CA

Walter has a background in both neuroscience research and clinical product development. As a research scientist, Dr. Greenleaf has focused on age-related changes in the human neuroendocrine system, and the effects of hormones on mood and behavior. His PhD is in Neuro- and Bio-Behavioral Sciences, from Stanford University. His most recent academic appointment was as Director for the Mind Division, Stanford Center on Longevity. As a medical product developer, Walter has designed and developed several clinical product streams: his focus has been on the use of simulation and telemedicine technology to treat difficult problems in behavioral and physical medicine.  Dr. Greenleaf founded and served as CEO for: Greenleaf Medical Systems, a business incubator; InWorld Solutions, specializing in the therapeutic use of virtual worlds for behavioral health care; and Virtually Better, which develops virtual environments for the treatment of phobias, anxiety disorders, and PTSD.

previous next

Walter

Beth Rogozinski

Chief Content Advisor

San Francisco, CA

Beth is a media technology professional, transmedia producer and marketing strategist.

She was a founding member of the internationally renowned Multimedia Studies Program at SFSU where she taught and published a book on multimedia. She then worked in hardware, software and services at such top firms as Silicon Graphics, Macromedia and the digital agency Circle, (bought by Euro RSCG).  Beth has since founded games and apps companies including Signal 2 Productions, Match Factor and D2S Games.  She helped produce and publish more than 30 casual games and apps, including apps for health care and wellness.

Beth is an advisor to many start-ups including the Mobile Monday Momentum Accelerator, Grimm Bros Games, Major League Wizardry and Digify.  In 2011, Beth founded Transmedia SF, an agency/studio/incubator/salon that boasts a community of over 5000 creatives and hosts regular educational and networking events.

previous next

Beth

Team

Daniel Barbosa

Director, Technical Operations

San Francisco

Daniel is passionate about Technical Operations and building robust, highly automated, secure infrastructures.  Having moved to San Francisco in 2000 and caught the tail end of the dot com boom, over the years he has worked for several Bay Area startups.

Prior to joining Pear, Daniel worked as a DevOps consultant, helping companies take advantage of the latest best practices and tooling to speed up their ability to deliver on their ideas.

previous next

Daniel

Hilary Luderer

Director, Clinical Operations

Boston

Hilary is a scientist and writer. Her diverse scientific background includes bone and mineral biology, tissue repair and regeneration and inborn errors of metabolism.

Prior to joining Pear, Hilary was an analyst in the Rare Genetic Diseases group at Agios Pharmaceuticals where she contributed to pipeline development, hypothesis generation and strategic planning. She has also worked as a scientific manuscript editor for American Journal Experts.

Hilary holds a BS in Chemistry from the University of Michigan and a PhD in Cell and Molecular Biology from Washington University in St. Louis. Her postdoctoral training was at Massachusetts General Hospital and Harvard University.

previous next

Hilary

Jason Ma

Technical Director

San Francisco

Jason is a believer in building lean and strives to find the balance between doing things right and doing things fast. Since joining Pear Therapeutics, he has helped shape the design and architecture of the software platform and pushed for better product and user experience.

Jason graduated from the University of Alberta, Canada with a B.Sc in Computer Engineering. Always looking for adventure, Jason has worked in Canada, New Zealand, and Silicon Valley.

previous next

Jason

Phu Trinh

Director, Software Quality Assurance and Compliance

San Francisco

Phu Trinh spent over 22 years building companies from start-up stage to successful M&A. His journey took him across companies in digital healthcare, eCommerce, eDiscovery, digital ticketing, medical devices and application provisioning. Phu has experience in product management, software development, quality assurance, project management, implementation services and FDA compliance.

Phu’s highlights include Relsys’ Argus Safety (acquired by Oracle in 2009), Clearwell’s eDiscovery Platform (acquired by Symantec in 2011) and CenterRun’s application provisioning (acquired by Sun Microsystems – now Oracle in 2003).  As a co-founder of Relsys, Phu helped grow the company from 5 employees to over 40 employees.  Relsys was recognized as the Deloitte 50 Fastest Growing Company in Orange County, California.

Phu holds a Bachelor of Science in Electrical Computer Engineering from California State Polytechnic University, Pomona.

previous next

Phu

David Zuckerman

Director, Customer Engagement

Boston

David brings a unique skill set to Pear Therapeutics. After 8 years in the investment field, David decided to join the Pear Therapeutics team to focus on operations.

He began his career as a molecular biologist at the Dana-Farber Cancer Institute.  After three years as a researcher in a pediatric oncology lab, he joined the Centers for Disease Control and Prevention (CDC) to help set up and run a bioterrorism lab. After building and running the lab for three years, David was looking for a new challenge and was recruited by a top performing investment team at Merrill Lynch.

David received his BA in Biology from Skidmore College and is currently pursuing an MBA from Babson College.

previous next

David

Heather Browning

Product Manager

San Francisco

Heather is a product management leader with a background in cognitive psychology and behavioral economics. A startup veteran, she is experienced in interfacing with enterprise/legacy systems.

Heather specializes in structuring product design and execution, creating user models, and data-driven design frameworks with a focus on new products and strategic initiatives.

previous next

Heather

Charles Green

Product Manager

San Francisco

Charles is a product thinker and creative technologist. At Pear, he helps build the safest, most effective products possible.

In 2013, Charles founded Symmetry Labs, a creative agency specializing in custom LED lighting systems. Charles has also worked as a software engineer and web developer.

Outside the office, Charles is a semi-professional acrobat and, way back when, a yoga teacher.

previous next

Charles

Sarmad Abdullah

Software Engineer

San Francisco

Sarmad is a software and technology enthusiast. He started programming as a hobby when he was 12 years old, and he spent more than 15 years in professional software development across various industries including games, desktop tools, and web development.

With experience in dozens of software technologies and programming languages, his knowledge of computer technologies spans the entire stack from low level programming to high level systems and architectures. He has written code for Honda, Nokia, Microsoft, and few other companies during his career, and he has targeted mobile devices, desktops, web browsers, as well as backend and database servers.

Sarmad is the author of Alusus programming language, an open-source multi-purpose programming language that he designed in his spare time in a hope to make the programming landscape simpler and more efficient for the new generations of programmers. He spends his spare time writing articles and blog posts about software development. When it comes to coding habits, Sarmad strives for simplicity as well as proper software design principles, but he tries to balance those with efficient coding.

Sarmad has a B.Sc. in computer engineering.

previous next

Sarmad

Jillian Ahrens

Product Designer

San Francisco

For the past 10 years, Jillian has been designing seamless user experiences and visual solutions to solve complex problems.

At Deloitte Digital and Cloud City Development, she wove meaningful and innovative digital interactions into people’s lives across a broad range of corporate, academic, and non-profit clients: omni-channel experiences for JCPenney, pharmaceutical CRMs for Eli Lilly, interactive tutorials for MIT Maker Labs, responsive web applications for Principal Financial and San Francisco PRIDE, customer- and sales-facing mobile platforms for Amtrak, digital roadmap workshops for T.J.Maxx C-Suite and stakeholders.

The opportunity to push the boundaries of integrated design and development at Pear Therapeutics is a cornerstone in Jillian’s career. At the heart of her work is a deep conviction that building successful products hinges on strong team and stakeholder relationships and communication. Jillian is motivated by her team and the opportunity to contribute to the positive impact Pear’s products will have on the wellbeing of millions of people.

previous next

Jillian

Katherine Coolidge

Manager of Commercial Operations

Boston

Katherine is a business analyst with a background in the retail and pharmacy industries. She joined Pear after working on both the strategic initiatives team and the pricing & analytics team at CVS Health where she worked on a diverse range of projects including ones in digital healthcare and commercial strategy. She began her career working for several successful start-ups in the retail industry.

Katherine graduated from Boston University with a B.S. in Business Administration, and is currently pursuing her master’s degree in Applied Business Analytics from Boston University.

previous next

Katie

Joya Joseph

Software Engineer

San Francisco

Joya is a proud alumna of the University of South Carolina School of Engineering, where she obtained her BS in Electrical Engineering with an emphasis in AI.  She went on to work in military robotics, financial, and freight industries.

Always learning, Joya is enthusiastic to tackle every new logic problem she can find. Joining the Pear Therapeutics team has allowed her to use her talents to expand the reach of key therapeutics to the users who need it most.

previous next

Joya

Celine Otter

Software Engineer

San Francisco

Celine is excited to be a part the engineering team developing meaningful web and mobile applications within the healthcare industry. She loves how dynamic, creative and collaborative Software Engineering can be. The team strongly values full test coverage, TDD and pair programming which challenge each member’s thought process, idea communication and execution precision daily. Previously, she worked for a large education incubator as well as for a cyber security company.

Celine has a B.S. in Human Sciences and a M.S. in International Healthcare Management. Prior to transferring into tech, she gained a broad range of experiences within healthcare. This includes working in business development for a Biotech firm in Beijing and being an analyst in Health Information Management in LA. She also delivered a consultancy project to the UK Department of Health, as well as to Medtronic Inc..

Beyond coding, some critical skills she developed since immersing herself in the Californian way of life include surfing, rock climbing and most recently swing dancing.

previous next

Celine

Eliot Lash

Software Engineer

San Francisco

Eliot is a full-stack engineer specializing in mobile front-end development. Before joining Pear, he worked for Disney Mobile and freelanced as an independent game developer. Eliot is excited to be part of the Pear team because it offers a unique opportunity to create innovative therapeutics powered by high quality, test-driven code.

previous next

Eliot

Jessica Lipschitz, PhD

Clinical Lead

Boston

Dr. Lipschitz is a licensed, clinical psychologist. She has eight years of experience in digital behavioral health, developing, evaluating, and implementing technology-based interventions in academic, government and industry settings. Her work has spanned a wide array of health concerns including depression, addiction, adherence, sleep, diet, exercise, anxiety, and self-management of chronic medical conditions.

Dr. Lipschitz maintains a clinical practice and an academic research program at Brigham and Women’s Hospital/Harvard Medical School.  Her research focuses on initiatives to improve eHealth options in new therapeutic areas and improve usability and implementation of existing technology-based behavioral health interventions.  She is widely published and sits on the Association for Behavioral and Cognitive Therapies Continuing Education Committee.  She is also a guest editor for the Journal of Internet Medical Research, Cognitive and Behavioral Practice, and Psychiatry Research.

Dr. Lipschitz completed her doctoral work at the University of Rhode Island under the mentorship of James Prochaska, a world leader in the field of technology-based behavioral health interventions and motivational tailoring. Her clinical internship was at the Boston VA Healthcare System/Harvard Medical School in General Mental Health. She earned her BA from Brown University.

previous next

Jessi

Tony Ngan

Quality Assurance

San Francisco

Tony is motivated by the prospect to help deliver high quality Prescription Digital Therapies in Pear’s pipeline.  Having worked as contributor as well as QA lead at Netscape/AOL, RedHat, Affinity Circles, Linden Lab, and Covia Lab, he has well rounded experience in QA methodology, automation, load and performance testing against backend servers, social networking sites, games, web and mobile applications.

Tony holds a Computer Science degree from UC Berkeley.

previous next

Tony

Eric Shen

Business Analyst

Boston

Eric has served as a research assistant at the Mount Sinai hospital, a histology lab technician at Robert Wood Johnson University, and a bioinformatics intern at New York University Langone Medical Center.  He is published in the field of bioinformatics under Stuart Brown for helping create a draft genome of the coffee berry borer.   Eventually developing a passion for business alongside healthcare, Eric has pursued administrative, marketing, and business development positions prior to joining Pear as an operations analyst.

Eric is a graduate of Brandeis University with a B.A in Biology and a minor in Business.  In the future, he plans to go back to business school in order to pursue his M.B.A.

previous next

Eric

Monica Alves

Bookkeeper and Office Manager

Boston

Monica Alves has an interesting background. She earned her B.A. in Legal Studies and minored in Economics from the University of Massachusetts, Amherst.

Monica had a passion for law and began her career working at prominent law firms: Harmon Law Offices, P.C. and LibbyHoopes, P.C., where she provided administrative/legal support. After working in the legal field for a few years, Monica decided to switch things up and started working as a marketing associate at Cerulli Associates, a financial research company.

After a few years, the company noticed Monica’s unique skill set and offered her a position to handle the company’s finances and report directly to the CEO of the company. She accepted and that is how she began her career in accounting.

After 5 years at the company, Monica decided to join Pear Therapeutics as their Bookkeeper and Office Manager.

previous next

Monica

Everett Crosland

Executive Director of Market Access & Reimbursement

Boston

Accomplished Head of Market Access & Reimbursement with significant experience in developing and executing innovative reimbursement, pricing, and managed markets commercialization and launch strategies.

Proven expertise and leadership in launching and commercializing novel oral, injectable, and inhaled therapeutics and drug-device combinations used to treat rare and common diseases.

Demonstrated programmatic leadership and execution of global, national, and company-wide initiatives. Experience in leading teams and cross-functional initiatives focused on forecast-moving programs.

previous next

Everett

Heather Schapiro

Head of Data Science

San Francisco

Heather is a neuroscience PhD with 10+ years experience in research in data. Her passion is the intersection of innovation and scientific discovery, for the purpose of commercializing novel tools to promote human health.

As Lead Data Scientist at Pebble, the first-ever smartwatch company, Heather focused on the development and optimization of Pebble Health. She wrangled data to impact the organization at many levels, including analytics & business intelligence, data-driven product development, and R&D for forward-thinking products. Prior to Pebble, Heather used brain imaging and human behavior studies to examine neural circuits implicated in developmental disorders. She continues to support the innovation of novel health discoveries as Analyst-in-Residence at HealthTech Capital, a group of investors dedicated to funding and mentoring new start-ups at the intersection of healthcare and technology. As Head of Data Science at Pear, Heather is beyond thrilled to be leveraging data to set the precedent for digital therapeutics.

Outside of the office, Heather loves triathlon training and outdoor adventure.

previous next

Heather

The Board of Directors

Corey McCann, MD, PhD

Founder and Chief Executive Officer

Boston, MA • San Francisco, CA

Corey is a physician, scientist, entrepreneur, and healthcare investor.

Previously, he was an investor with MPM Capital and with RiverVest Venture Partners, where he evaluated new investment opportunities, managed relationships with strategic partners, and oversaw board-level strategy and execution at portfolio companies. Prior to MPM, he was with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey’s Central Nervous System (CNS) expertise group, serving clients across pharma and biotech.  He is a founding member of multiple start-ups including Alcyone Lifesciences, a company developing technologies to deliver therapeutics to the brain.

Dr. McCann’s post-graduate training was at Harvard University, Washington University in St Louis, and at the Massachusetts General Hospital, and he graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar.

previous next

Corey

Zack Lynch

Board Director

JAZZ Venture Partners • San Francisco, CA

Zack Lynch is General Partner at JAZZ Venture Partners.

Zack is an entrepreneur, market maven and futurist who brings a rich understanding of the technologies and companies driving the experiential technology market to JAZZ.  He is the founder and chairman of the Neurotechnology Industry Organization (NIO), a global trade association of over 120 companies involved in developing treatments for neurological diseases, psychiatric illnesses and nervous system injuries. He is the founder and curator of the Experiential Technology and NeuroGaming Conference and Expo which is the leading meeting bringing together tech executives, game designers, neuroscientists and investors focused on improving human performance. He is the author of the best-selling book, The Neuro Revolution: How Brain Science Is Changing our World published by St. Martin’s Press.

previous next

Zack

Timothy Petersen

Board Director

Arboretum Ventures • Ann Arbor, MI

Tim Petersen joined Arboretum Ventures as a Managing Director in 2002.

Tim’s investment focus has been shaped by his broad business experience with creating, growing, and financing entrepreneurial firms. His investments primarily target capital-efficient companies in medical technology, health IT and services that redefine efficient models for care delivery and improve access to care. Tim has led investments and held board seats in more than a dozen portfolio companies during his tenure with Arboretum. Tim led Arboretum’s investment into health IT company HealthMedia, which was acquired by J&J in 2008. He also led Arboretum’s investment into Accuri Cytometers, which was acquired by BD in 2011 for $205 million and Inogen, which went public in 2014. An innovator in the delivery of oxygen to patients with COPD, Inogen’s market capitalization exceeded one billion in 2015.

From 1999 to 2002, he helped establish the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan, serving as its Managing Director. The Institute has been consistently ranked as one of the top three entrepreneurship programs in the country. During his tenure at Michigan, he also directed the activities of the Wolverine Venture Fund, the Institute’s venture capital fund focusing on early-stage life science and technology investments. Prior to Michigan, Tim was a manager in the investment banking practice at Plante Moran Corporate Finance and served as a management consultant at Industrial Economics, Inc. in Cambridge, MA

previous next

Tim

Andrew J. Schwab

Board Director

5 AM Ventures • San Francisco, CA

Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (IPO), Ikaria (acquired by Madison Dearborn Partners), Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.

previous next

Andrew

Mira Chaurushiya, PhD

Board Observer

5 AM Ventures • San Francisco, CA

Mira Chaurushiya, Ph.D. joined 5AM Ventures as an Associate in 2015 from Genentech, where she was a Postdoctoral Fellow in the Department of Physiological Chemistry studying mouse models of cancer and stem cells.

Dr. Chaurushiya currently serves as an Observer on the Boards of Chrono Therapeutics, Precision Nanosystems and Startide Sciences. She is a Fellow of the Society of Kauffman Fellows. Prior to Genentech, Dr. Chaurushiya completed her Ph.D. work at the Salk Institute, where she studied Herpes Simplex Virus infections and epigenetics. Her work has been published in Science and PNAS, among others.

Dr. Chaurushiya received a Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received her B.A. in Biology from Carleton College. Dr. Chaurushiya is based in the San Francisco, CA office.

previous next

Mira

John Harris

Board Observer

JAZZ Venture Partners • San Francisco, CA

John is a General Partner at JAZZ Venture Partners and brings significant experience founding, funding and developing early-stage life sciences and technology companies.  Prior to JAZZ, John was the founder, President and CEO of NeuroVista, a Seattle-based medical device company pioneering new technologies for the management and treatment of epilepsy.  NeuroVista was acquired by Cyberonics in 2013 (NASDAQ: CYBX).  John was also a founder and the Vice President of Marketing and Business Development at Northstar Neuroscience, which went public in 2006 (NASDAQ:  NSTR) and was subsequently acquired by St. Jude Medial (NYSE:  STJ).  Prior to founding Northstar, he was a founder of Heartstream, a company that revolutionized the treatment of sudden cardiac arrest with uniquely designed external defibrillators that remain the market leader and can be found in airports, airplanes, stadiums, public buildings and many other locations.  Heartstream went public in 1996, was subsequently acquired by Hewlett-Packard (NYSE: HPQ).

John holds a BS in industrial engineering from Stanford University and an MBA from Northwestern University’s Kellogg School of Management.

previous next

John

Tom Shehab, MD

Board Observer

Arboretum Ventures • Ann Arbor, MI

Tom Shehab, M.D., joined Arboretum Ventures in 2014 as a Principal.

Previously, Tom served as a member of Arboretum’s Technical Advisory Board and as a board member of an Arboretum portfolio company, ArborMetrix. In his current role, Tom draws upon his clinical, healthcare administration and operational expertise to evaluate new potential investments and provide strategic support to Arboretum’s portfolio companies.

Prior to joining Arboretum, Tom spent 12 years as a physician executive and practicing physician specializing in gastroenterology. He was involved in a number of entrepreneurial healthcare related ventures and held multiple senior leadership roles. Most recently, Tom served as Chief of Staff for more than 1,000 physicians at St. Joseph Mercy Hospital in Ann Arbor and as the Chair of Medicine for Integrated Health Associates (IHA), a multi-specialty group consisting of 300+ providers. Both St. Joseph Mercy Hospital and IHA are part of Trinity Health.

previous next

Tom

Jeremy Sohn

Board Observer

Novartis • Allston, MA

Mr. Sohn is a serial technology entrepreneur and venture capitalist. He is currently the VP, Head of Business Development and Licensing at Novartis where he is responsible for leading all-digital, technology driven, business development activities.

Prior to Novartis, Jeremy was a Managing Director at MPM Capital where he was responsible for leading MPM’s life sciences-focused digital innovation investment strategy. At MPM, Jeremy personally founded two companies: CentrosHealth (acquired by Clinical Ink in March 2015), a mobile, patient-engagement platform designed to improve the patient experience during clinical trials, and TriNetX, a federated network of clinical data warehouses that optimizes clinical trial protocol design and patient recruitment.

Jeremy is a frequent speaker on digital innovation within healthcare and life sciences and is a member of the Advisory Committee for SMART Platforms.org, a public-private consortium developing an open source data interoperability platform that enables third-party application development and integration with EHRs.

Jeremy graduated cum laude from Princeton University’s Woodrow Wilson School of Public and International Affairs, with a focus on biotechnology and medical policy.

previous next

Jeremy

The Advisory Board

Patrick Kennedy

Chair of Advisory Board and Advisor on Healthcare Policy and Reimbursement

Boston, MA

Representative Patrick Kennedy served 16 years in the U.S. House of Representatives, and is predominantly known as author and lead sponsor of the Mental Health Parity and Addiction Equity Act of 2008. This dramatic piece of legislation provides tens of millions of Americans who were previously denied care with access to mental health treatment. Rep. Kennedy is now the co-founder of One Mind, a national coalition seeking new treatments and cures for neurologic and psychiatric diseases of the brain afflicting one in every three Americans. One Mind is dedicated to dramatic enhancements in funding and collaboration in research across all brain disorders in the next decade. Rep. Kennedy is also the founder of the Kennedy Forum on Community Mental Health which served as a vehicle to celebrate the 50th anniversary of President Kennedy’s signing of the Community Mental Health Act, the landmark bill that laid the foundation of contemporary mental health policy and provided Rep. Kennedy with the platform to launch a bold, ongoing effort to advance the work President Kennedy began. The Kennedy Forum continues to advocate for mental health parity.

previous next

Patrick

Lisa Marsch, PhD

Advisor on Content Development for SUD

Hanover, NH

Lisa A. Marsch, PhD. is the Director of the Center for Technology and Behavioral Health (CTBH), a “Center of Excellence” supported by the National Institute on Drug Abuse, focused on using science to inform the development, systematic evaluation, and sustainable implementation of digital therapeutic tools for substance use disorders and other areas of behavioral health.  These tools leverage web, mobile, sensing, and/or social media approaches to deliver engaging and effective health behavior interventions and to collectively lead to transformations in the delivery of science-based health care. CTBH is housed at Dartmouth College but includes interdisciplinary partners across the U.S. and internationally.

Dr. Marsch is also the Director of the Northeast Node of the National Drug Abuse Clinical Trials Network and the Andrew G. Wallace Professor within the Geisel School of Medicine at Dartmouth College.

Dr. Marsch has personally led many research initiatives on technology and behavioral health totaling over $50 million in grant funding, largely from the National Institutes of Health.    Her work in technology and addiction treatment has been particularly pioneering, as she is widely recognized as having led the development of the most widely tested and evidence-based mobile intervention for addiction treatment.

Dr. Marsch publishes extensively and is a regular keynote speaker at national and international scientific meetings (including invited presentations at the White House, Congressional briefings, the World Bank, and for the US Surgeon General).

She has served as a consultant to the Department of Mental Health and Substance Abuse at the World Health Organization.  She serves on the National Advisory Council to the National Institute on Drug Abuse at the National Institutes of Health.  She has also served on the Health Information Technology Policy Committee on Advanced Health Models and Meaningful Use for the U.S. Office of the National Coordinator.

previous next

Lisa

Eric Leuthardt, MD

Advisor on Intellectual Property

St. Louis, MO

Eric C. Leuthardt, M.D. is a neurosurgeon who is currently an associate professor with the Department of Neurological Surgery and the Department of Biomedical Engineering at Washington University in St. Louis. He is Director of the Center for Innovation in Neuroscience and Technology. He received his B.S. in Biology and Theology at St. Louis University in 1995 and received his M.D. at the University of Pennsylvania’s School of Medicine in 1999. He went on to complete his training at Barnes Jewish Hospital and Washington University in St. Louis in 2005 and then went on to pursue a combined fellowship in epilepsy and spinal surgery at the University of Washington in Seattle in 2006. His research has focused on neuroprosthetics – devices linked to the brain that may lead to cures for paralysis, allow patients to move artificial limbs, or restore other neurological functions. His work in the field of neuroprosthetics and neurosurgical devices has yielded him numerous accolades as a scientist, a neurosurgeon, and an inventor. Among other awards, Eric was named one of the Top Young Innovators by MIT’s magazine, Technology Review. In addition to the above, Eric was author of several of Pear’s core patents, covering clinical applications of eFormulations.

previous next

Eric

Magali Haas, MD, PhD, MSE

Advisor on Pharmaceutical Industry Partnerships

New York, NY

Dr. Haas is Founder and CEO of Orion Bionetworks, a nonprofit corporation dedicated to accelerating the discovery of next-generation diagnostics, treatments, and cures for brain disorders by harnessing the power of high-performance computing and data analytics to discover and develop predictive disease models from integrated biomarker, biosensor and phenotypic data. She also served 3 years as Chief Science and Technology Officer for One Mind for Research, a nonprofit organization launched in May 2012 by Patrick J Kennedy. She orchestrated the launch of One Mind’s seminal programs, Apollo, an informatics research portal and, Gemini, an international TBI/PTSD research program. Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. As an “intrapreneur” at J&J she established the first Neuroscience Integrative Solutions department, and co-founded the first Companion Diagnostics Center of Excellence as well as the first Healthcare Innovation team. She serves on several advisory boards including Brain Canada, the International Neuroinformatics Coordinating Facility, and IMEC for nano electronics and biosensors.

previous next

Magali

JoAnn Difede, PhD

Advisor on Clinical Development

New York, NY

JoAnn Difede, Ph.D. is a Professor in the Department of Psychiatry at Weill Medical College of Cornell University, an Attending Psychologist at the New York-Presbyterian Hospital/Weill Cornell Medical Center, and Director of the Program for Anxiety and Traumatic Stress Studies (PATSS). She is internationally recognized for her pioneering work using virtual reality technology in the treatment of PTSD consequent to the WTC attack of September 11, 2001, and more recently in the treatment of combat-related PTSD. Dr. Difede is currently serving as the lead PI of a large multi-site Department of Defense funded clinical trial contract entitled, “Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with a Cognitive Enhancer,” which is investigating how the use of virtual reality and the pharmacologic agent, D-Cycloserine, may help accelerate recovery from combat-related PTSD among U.S. service members deployed to Iraq and Afghanistan. Dr. Difede has served as the PI of several NIH-funded treatment studies concerning the development of innovative treatments for PTSD. She received the 2010 Award for Outstanding Contributions to the Practice of Trauma Psychology from the American Psychological Association’s Division of Trauma. In addition to her scholarly endeavors, her work has been featured in many popular media venues including the New Yorker, the NY Times, Newsweek, the Washington Post, Scientific American, and many television programs, including a recent appearance on Charlie Rose: The Brain Series’ episode on PTSD, CNN, NBC, and ABC’s World News Tonight with Peter Jennings.

previous next

JoAnn

Albert Rizzo, PhD

Advisor on VR Therapeutics

Los Angeles, CA

Psychologist Albert “Skip” Rizzo conducts research on the design, development and evaluation of virtual reality (VR) systems targeting the areas of clinical assessment, treatment rehabilitation and resilience. This work spans the domains of psychological, cognitive and motor functioning in both healthy and clinical populations. Rizzo, whose work using virtual reality-based exposure therapy to treat PTSD received the American Psychological Association’s 2010 Award for Outstanding Contributions to the Treatment of Trauma, is the associate director for medical virtual reality at the USC Institute for Creative Technologies.

He also holds research professor appointments with the USC Department of Psychiatry and Behavioral Sciences and at the USC Davis School of Gerontology. Rizzo is working with a team that is creating artificially intelligent virtual patients that clinicians can use to practice skills required for challenging clinical interviews and diagnostic assessments. His cognitive work has addressed the use of VR applications to test and train attention, memory, visuospatial abilities and executive function.

In the motor domain, he has developed VR game systems to address physical rehabilitation post stroke and traumatic brain injury and for prosthetic use training. He is currently designing VR scenarios to address social and vocational interaction in persons with autistic spectrum disorder.

Rizzo is currently examining the use of VR applications for training emotional coping skills with the aim of preparing service members for the stresses of combat. He is senior editor of the MIT Press journal, Presence: Teleoperators and Virtual Environments. He also sits on a number of editorial boards for journals in the areas of cognition and computer technology (Cognitive Technology; Journal of Computer Animation and Virtual Worlds; Media Psychology) and is the creator of the Virtual Reality Mental Health Email Listserve (VRPSYCH).

previous next

Albert

Alex Pentland, PhD

Advisor on Big Data Strategies

Boston, MA

Alex “Sandy” Pentland has helped create and direct MIT’s Media Lab, the Media Lab Asia, and the Center for Future Health. He chairs the World Economic Forum’s Data Driven Development council, is Academic Director of the Data-Pop Alliance, and is a member of the Advisory Boards for Google, Nissan, Telefonica, the United Nations Secretary General, Monument Capital, and the Minerva Schools. In 2012 Forbes named Sandy one of the ‘seven most powerful data scientists in the world’, along with Google founders and the CTO of the United States, and in 2013 he won the McKinsey Award from Harvard Business Review. He is among the most-cited computational scientists in the world, and a pioneer in computational social science, organizational engineering, wearable computing (Google Glass), image understanding, and modern biometrics. His research has been featured in Nature, Science, and Harvard Business Review, as well as being the focus of TV features on BBC World, Discover and Science channels. His most recent book is `Social Physics,’ published by Penguin Press. Sandy’s research group and entrepreneurship program have spun off more than 30 companies to date, three of which are publicly listed and several that serve millions of poor in Africa and South Asia. Recent spin-offs have been featured in publications such as the Economist and the New York Times, as well as winning a variety of prizes from international development organizations.

previous next

Alex

Harold Koplewicz, MD

Advisor on Child and Adolescent Psychiatry

New York, NY

Dr. Koplewicz is one of the nation’s leading child and adolescent psychiatrists. He is widely recognized as an innovator in the field, a strong advocate for child mental health, and a master clinician. He has been repeatedly recognized in America’s Top Doctors, Best Doctors in America, and New York Magazine’s Best Doctors in New York. Dr. Koplewicz is the President of the Child Mind Institute, the only independent non-profit organization exclusively dedicated to transforming mental healthcare for the world’s children. The Child Mind Institute is developing new and innovative treatments, building the science of healthy brain development and providing scientifically sound information about normal development, parenting and psychiatric disorders in children and adolescents an (childmind.org) to parents, educators and health professionals. Dr. Koplewicz has served as a member of the National Board of Medical Examiners and as a Commissioner of the New York State Commission on Youth, Crime and Violence and Reform of the Juvenile Justice System. Since 1997, Dr. Koplewicz has been the Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology. He was also a member of the working group organized by the U.S. Assistant Surgeon General and the U.S. Department of Health and Human Services to address the effects of terrorism on children’s mental health. Most recently he was selected to be a member of the mental health and disabilities working group of Vice President Joe Biden’s Task Force on Gun Violence. He has been at the forefront of public education to dispel the myths and stigma surrounding psychiatric disorders of children and adolescents. He has appeared regularly on national media and press discussing this topic.

previous next

Harold

Jeffery Lieberman, MD

Advisor on Pharmacotherapies in Psychiatry

New York, NY

Jeffrey A. Lieberman, MD, is a physician and scientist who has spent his career of over 25 years caring for patients and studying the nature and treatment of mental illness. He is the Lawrence C. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as Psychiatrist in Chief at NewYork-Presbyterian Hospital – Columbia University Medical Center. Dr. Lieberman’s research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations and has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs. In terms of the latter, he served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH. He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent the debilitating effects of schizophrenia and related psychotic disorders.

previous next

Jeffery